Formulation and Characterization of RBCS Coated Carboplatin Loaded Nano-Liposomal Formulation for Managing Breast Cancer

IF 3.5 4区医学 Q2 CHEMISTRY, MEDICINAL

Drug Development Research Pub Date : 2024-11-19 DOI:10.1002/ddr.70019

Akhilesh Dubey, Faby Raju, Cynthia Lizzie Lobo, Ravi Gs, Srinivas Hebbar, Amitha Shetty, Pankaj Kumar, Sally A. El-Zahaby

{"title":"Formulation and Characterization of RBCS Coated Carboplatin Loaded Nano-Liposomal Formulation for Managing Breast Cancer","authors":"Akhilesh Dubey, Faby Raju, Cynthia Lizzie Lobo, Ravi Gs, Srinivas Hebbar, Amitha Shetty, Pankaj Kumar, Sally A. El-Zahaby","doi":"10.1002/ddr.70019","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Cell membrane-coated Nano-Liposomes (CM-NLPs) offer a promising approach that combines the advantages of both host cells and synthetic nano-liposomes (NLPs). This technique involves coating liposomes with red blood cell (RBC) membranes to enhance their functionality. In this study, novel carboplatin-loaded NLPs (CP-NLPs) were formulated using phospholipids (Soya Phosphatidyl Choline) and cholesterol through the thin-film hydration method, and optimized using a 3<sup>2</sup> full factorial design. The optimized CP-NLPs were coated with RBC membranes, resulting in the formulation “CP-RBCs-NLPs.” These were characterized for particle size, zeta potential, entrapment efficiency, transmission electron microscopy (TEM), differential scanning calorimetry (DSC), protein content, in vitro drug release, cell viability, and stability. The optimized CP-RBCs-NLPs exhibited a particle size of 103.6 nm, with zeta potential values of −27.3 mV indicating good stability. The entrapment efficiency was approximately 56%, and the drug release profile showed sustained release for up to 8 h. Cytotoxicity studies in human triple-negative breast cancer (MDA-MB468) cell lines demonstrated that CP-RBCs-NLPs effectively delivered the drug into target cells, facilitating cell death due to their bilayer structure similar to cell membranes. Overall, CP-RBCs-NLPs outperformed both carboplatin-loaded conventional NLPs (CP-CNLPs) and carboplatin-conventional solution (CP-CNS), making it a superior formulation for drug delivery.</p>\n </div>","PeriodicalId":11291,"journal":{"name":"Drug Development Research","volume":"85 8","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ddr.70019","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Cell membrane-coated Nano-Liposomes (CM-NLPs) offer a promising approach that combines the advantages of both host cells and synthetic nano-liposomes (NLPs). This technique involves coating liposomes with red blood cell (RBC) membranes to enhance their functionality. In this study, novel carboplatin-loaded NLPs (CP-NLPs) were formulated using phospholipids (Soya Phosphatidyl Choline) and cholesterol through the thin-film hydration method, and optimized using a 3² full factorial design. The optimized CP-NLPs were coated with RBC membranes, resulting in the formulation “CP-RBCs-NLPs.” These were characterized for particle size, zeta potential, entrapment efficiency, transmission electron microscopy (TEM), differential scanning calorimetry (DSC), protein content, in vitro drug release, cell viability, and stability. The optimized CP-RBCs-NLPs exhibited a particle size of 103.6 nm, with zeta potential values of −27.3 mV indicating good stability. The entrapment efficiency was approximately 56%, and the drug release profile showed sustained release for up to 8 h. Cytotoxicity studies in human triple-negative breast cancer (MDA-MB468) cell lines demonstrated that CP-RBCs-NLPs effectively delivered the drug into target cells, facilitating cell death due to their bilayer structure similar to cell membranes. Overall, CP-RBCs-NLPs outperformed both carboplatin-loaded conventional NLPs (CP-CNLPs) and carboplatin-conventional solution (CP-CNS), making it a superior formulation for drug delivery.

查看原文本刊更多论文

用于治疗乳腺癌的 RBCS 包覆卡铂载药纳米脂质体制剂的配制和特性分析

细胞膜包被纳米脂质体（CM-NLPs）是一种很有前景的方法，它结合了宿主细胞和合成纳米脂质体（NLPs）的优点。这种技术是用红细胞膜包裹脂质体，以增强其功能。本研究利用磷脂（大豆磷脂酰胆碱）和胆固醇，通过薄膜水合法配制了新型卡铂负载型纳米脂质体（CP-NLPs），并采用 32 全因子设计对其进行了优化。优化后的 CP-NLPs 涂覆在 RBC 膜上，形成 "CP-RBCs-NLPs "配方。对这些制剂的粒度、ZETA电位、包埋效率、透射电子显微镜（TEM）、差示扫描量热仪（DSC）、蛋白质含量、体外药物释放、细胞活力和稳定性进行了表征。优化后的 CP-RBCs-NLPs 的粒径为 103.6 nm，zeta 电位值为 -27.3 mV，具有良好的稳定性。在人类三阴性乳腺癌（MDA-MB468）细胞系中进行的细胞毒性研究表明，CP-RBCs-NLPs 能有效地将药物输送到靶细胞中，由于其双层结构与细胞膜相似，能促进细胞死亡。总体而言，CP-RBCs-NLPs 的性能优于卡铂载药传统 NLPs（CP-CNLPs）和卡铂传统溶液（CP-CNS），是一种出色的给药配方。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Development Research 医学-药学

CiteScore

6.40

自引率

2.60%

发文量

104

审稿时长

6-12 weeks

期刊介绍： Drug Development Research focuses on research topics related to the discovery and development of new therapeutic entities. The journal publishes original research articles on medicinal chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, and drug delivery, formulation, and pharmacokinetics. The journal welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy, and regulatory issues involving the drug discovery and development process. In addition to full-length articles, Drug Development Research publishes Brief Reports on important and timely new research findings, as well as in-depth review articles. The journal also features periodic special thematic issues devoted to specific compound classes, new technologies, and broad aspects of drug discovery and development.